GNPX News and Press, Genprex Inc. From 01/31/24

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that on Feb. 2, 2024, the company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.0...

2024-01-31 09:00:19 ET More on Genprex Seeking Alpha’s Quant Rating on Genprex Financial information for Genprex Read the full article on Seeking Alpha For further details see: Genprex to effect 1-for-40 reverse stock split to regain Nasdaq compliance

Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 PR Newswire AUSTIN, Texas , Jan. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-cha...

Genprex Provides Business Update and Outlook for 2024 PR Newswire Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024 Poised for FDA guidance regarding diabetes gene therapy program in 2024 AUSTIN, Texas , ...

Genprex was granted orphan drug designation by the FDA earlier this year for development of REQORSA combined with Tecentriq in small cell lung cancer Use of REQORSA combined with Tecentriq is the subject of Genprex’s upcoming Acclaim-3 clinical trial Genprex took part in two events in ...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Genprex Inc. (GNPX) is expected to report $-0.11 for Q3 2023

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general counsel and chief strategy officer, will be providing an overview of the company’s gen...

Genprex to Present at BIO-Europe 2023 Conference PR Newswire Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC AUSTIN, Texas , Nov. 1, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is hosting an upcoming virtual key opinion leader (“KOL”); the event will focus on the current state of lung cancer treatments and the ...